As of 2026-03-30, the Relative Valuation of Myriad Genetics Inc (MYGN) is (36.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.28 USD, the upside of Myriad Genetics Inc based on Relative Valuation is -952.5%.
The range of the Relative Valuation is (33.96) - (39.44) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.5x - 10.1x | 9.0x |
| Forward P/E multiples | 8.7x - 16.3x | 9.7x |
| Fair Price | (33.96) - (39.44) | (36.49) |
| Upside | -893.6% - -1021.6% | -952.5% |
| Date | P/E |
| 2026-03-20 | -1.17 |
| 2026-03-19 | -1.21 |
| 2026-03-18 | -1.19 |
| 2026-03-17 | -1.22 |
| 2026-03-16 | -1.17 |
| 2026-03-13 | -1.19 |
| 2026-03-12 | -1.24 |
| 2026-03-11 | -1.29 |
| 2026-03-10 | -1.31 |
| 2026-03-09 | -1.23 |
| 2026-03-06 | -1.32 |
| 2026-03-05 | -1.31 |
| 2026-03-04 | -1.35 |
| 2026-03-03 | -1.35 |
| 2026-03-02 | -1.28 |
| 2026-02-27 | -1.18 |
| 2026-02-26 | -1.24 |
| 2026-02-25 | -1.22 |
| 2026-02-24 | -1.13 |
| 2026-02-23 | -1.12 |
| 2026-02-20 | -1.10 |
| 2026-02-19 | -1.12 |
| 2026-02-18 | -1.12 |
| 2026-02-17 | -1.15 |
| 2026-02-13 | -1.15 |
| 2026-02-12 | -1.16 |
| 2026-02-11 | -1.24 |
| 2026-02-10 | -1.30 |
| 2026-02-09 | -1.30 |
| 2026-02-06 | -1.31 |
| 2026-02-05 | -1.30 |
| 2026-02-04 | -1.35 |
| 2026-02-03 | -1.36 |
| 2026-02-02 | -1.40 |
| 2026-01-30 | -1.44 |
| 2026-01-29 | -1.42 |
| 2026-01-28 | -1.46 |
| 2026-01-27 | -1.51 |
| 2026-01-26 | -1.48 |
| 2026-01-23 | -1.50 |
| 2026-01-22 | -1.55 |
| 2026-01-21 | -1.49 |
| 2026-01-20 | -1.45 |
| 2026-01-16 | -1.51 |
| 2026-01-15 | -1.54 |
| 2026-01-14 | -1.56 |
| 2026-01-13 | -1.58 |
| 2026-01-12 | -1.68 |
| 2026-01-09 | -1.68 |
| 2026-01-08 | -1.68 |